Synergistic intravesical instillation for bladder cancer: CRISPR-Cas13a and fenbendazole combination therapy. (2024)

Peer-Reviewed Study · Mingkang Liang; Yongqiang Wang; Lisha Liu et al. · August 12, 2024

Mingkang Liang et al., 2024-08-12: Liang et al. combine a CRISPR-Cas13a nanoplatform with intravesical fenbendazole nanoparticles in orthotopic bladder cancer, reporting apoptosis, PD-L1 suppression and immune remodelling.

In an orthotropic BCa model, the FBZ@BSA/FCS NPs demonstrated pronounced tumor cell apoptosis, synergistically reduced PDL1 expression, and restructured the immune microenvironment.

Mingkang Liang et al., 2024-08-12: Liang et al. combine a CRISPR-Cas13a nanoplatform with intravesical fenbendazole nanoparticles in orthotopic bladder cancer, reporting apoptosis, PD-L1 suppression and immune remodelling. Study type: bladder cancer cells plus an orthotopic mouse model. N: not stated in the abstract. Country: China. Dose: BSA@FBZ 0.36 mg/kg intravesically every three days (full text). Funder: not stated in the record. Declared conflicts: 'The authors have declared no competing interests.' Comparator: nanoparticles without fenbendazole and untreated tumours. This is a combination-device paper: the fenbendazole effect is not separable from the CRISPR arm. Study type: animal.